INTRODUCTION
Central nervous system (CNS) hemangiopericytoma (HPC) is a rare mesenchymal tumor which was first described by Stout and Murray [1] in 1942. HPC accounts for 2.5% of all meningeal tumors and <1% of all CNS tumors [2] [3] [4] . Since HPC is rare, prior reports about it are largely institutional retrospective studies, therefore, information about management of the disease is scarce. Recent studies insist that the extent of surgical resection and postoperative radiotherapy (RT) correlate with improved overall survival (OS) and recurrence-free survival (RFS). However, the definitions of complete resection or grossly total resection (GTR) in previous studies are equivocal [5] [6] [7] [8] . In most reported cases, since HPC is attached to the venous sinuses or major vessels, it is actually impossible to literally completely remove the tumor. Assuming that these ambiguous classifications on the extent of resection might have had a measurement bias, we reviewed the cases of 17 our patients with intracranial HPCs focusing on the clinical efficacy of surgical resection graded by Simpson grading system [9] (which is largely used in meningioma removal). The disease features, treatment strategies, and clinical courses of relevant cases from our experience were also analyzed.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of the pa-tients with intracranial HPC treated in our institute from January 1995 to December 2014 (i.e., the 20-year period). The total number of patients included was 17. The medical records of those patients were reviewed and analyzed by the authors. The following information was extracted: age, gender, radiologic finding (location, size, existence of adjacent vessels), pathology [World Health Organization (WHO) histopathological grade, Ki-67, mitosis], the extent of resection, radiation (total dose), Karnofsky performance scale (KPS) (preoperative and final score), length of follow-up, recurrence, metastases, and death. Radiologic findings, such as CT and enhanced MR images, were reviewed by experienced neuroradiologists. Operative records, including notes and video, were reviewed to determine gross tumor extension to adjacent vessels and completeness of resection. As in other papers, the extent of resection was divided into three categories (gross total resection, partial resection, biopsy); it was also divided into five categories by Simpson grading system (Table 1 ) [9] . The pathologic diagnoses and microscopic measurement were performed by experienced neuropathologist. Immunohistochemistry was done in all cases including Ki-67 proliferative index.
Approval for this study was granted by the Institutional Review Board of Seoul St. Mary's Hospital (approval numbers: KIRB 00513-1-002). Statistical analyses were performed using SPSS, version 17.0 (SPSS Inc., Chicago, IL, USA). The OS and RFS were calculated by the Kaplan-Meier analysis. The univariate analysis was conducted using log-rank test. p-value below 0.05 was considered statistically significant.
RESULTS

Patient characteristics
Patient demographic data are summarized in Table 2 . Between January 1995 and December 2014, for the 20-year period, a total of 17 patients underwent microsurgical resection for primary intracranial HPCs at least once. Additionally, a total number of 26 operations were performed for the resection of either primary or recurrent intracranial HPCs. The patient group included 14 (82.4%) males and 3 (17.6%) females. The median age at the time of the initial diagnosis was 48 years (range, 26-73). The most common presenting symptom was headache, followed by vomiting, visual field defects, and seizures.
The preferential area of tumor was parasagittal (8 patients, 47.1%), which is adjoined to superior sagittal sinus. Distributions of the other tumor locations were as follows: tentorial (3 patients, 17.6%), falx (2 patients, 11.8%), convexity (2 patients, 11.8%), cerebellopontine angle (1 patient, 5.9%), and sphenoid wing (1 patient, 5.9%). To evaluate the correlation between location and the extent of resection, these locations were grouped into 2 categories ( Table 2 ): those that adjoin adjacent vessels such as superior sagittal sinus, transverse sinus ( Fig. 1) , or sigmoid sinus, and those that have no adjacent major vessels (Fig. 2) . The results of Fisher's exact test suggest, that the extent of resection was statistically significantly associated neither with the location of tumor, nor with the existence of adjacent vessels (p=0.35 and 0.60, respectively).
Histopathological results of all specimens obtained in each surgery including recurrence were reviewed. 11 tumor specimens (42.3%) were confirmed WHO grade II HPCs and 15 tumor specimens (57.7%) were confirmed WHO grade III HPCs. Of total 17 patients, progression from low grade (WHO grade II) to anaplastic (WHO grade III) HPC was observed in 2 patients among 3 recurred patients (11.8%). The median Ki-67 proliferative index was 14%, with the range from 1% to 40%. In WHO grade II HPCs, the median Ki-67 proliferative index was 4.8%; in WHO grade III HPCs, it was 21.2%.
Treatment modalities
Treatment modalities consisted of surgery and adjuvant RT. All patients were initially treated with surgery and there were no perioperative mortalities and no unexpected events during the operations. At the initial operation, a GTR was accomplished in 16 cases (61.5%), a partial resection (PR) in 8 cases (30.8%), and an endoscopic biopsy in 2 cases (7.7%). By Simpson grading system (Table 1) , GTR was divided into 3 grades, grades 1 to 3. PR was the same as Simpson grade 4 and biopsy was same as Simpson grade 5. Dividing GTR group into Simpson grading system, grade 1 was done in 2 cases (7.7%), grade 2 in 11 cases (42.3%), and grade 3 in 3 patients (11.5%). In most cases, because of the location of tumor adjoined to the venous sinus, surgical resection was possible only by Simpson grade 2 or 3. Venous sinus was preserved in all patients. The location of tumor in 2 patients who underwent surgical resection by Simpson grade 1 was both at convexity. Surgical grading for recurred HPCs was also evaluated ( Table 2) . Table 2 ) rejected active treatment after initial surgery. The median 57.57 Gy (range, 50-60 Gy) was delivered in median 33 fractions (range, 30-40). 2 patients (11.8%) underwent stereotactic radiosurgery using cyberknife for the treatment of recurred HPC (total dose of 15 Gy and 27 Gy each, either by 3 fractions).
Clinical outcomes
The clinical outcomes were evaluated using the KPS. The median KPS at final outcome was 65 (initial median KPS was 65.8). The median follow-up period was 55 months, with the range from 10 to 197 months. 2 of the 17 patients died during the follow-up period, and the median OS was 13 months with median OS not reached (Fig. 3) . 5 patients (29.4%) developed local recurrence and the median RFS was 51 month (Fig. 4) .
Four types of subgroup analysis were performed for the following predictive factors with RFS: the extent of resection (conventional classification and Simpson grading), RT, and pathologic diagnosis. The median time for local recurrence of patient who underwent GTR was 68.3 months, PR was 37.1 months, and biopsy was 3.5 months (in this case, regrowth), which was statistically significant (p=0.003 by logrank test) (Fig. 5) . Additionally, the resection extent grades of intracranial HPC using Simpson grading system was significantly associated with higher RFS (p=0.011 by log-rank test) (Fig. 6) . Regarding adjuvant RT, the median time for local recurrence was 80. rank test) (Fig. 7) . Although the median time values for local recurrence were 66.2 months and 38.1 months in the patients with WHO grade II HPC and WHO grade III HPC, respectively, the pathological diagnosis of WHO grades II and III was not statistically significantly associated with the time for local recurrence (p=0.49 by log-rank test). Clinical follow-up and additional image studies, such as positron emission tomography-CT scans, did not suggest distant metastases.
DISCUSSION
HPC arises from Zimmerman pericytes around the endothelial lining of capillaries and postcapillary venules. Therefore, these tumors can occur anywhere where capillaries are found [1, 10] . However, in many reported cases, as well as in our experience, most of intracranial HPCs are located at parasagittal area or at tentorium which is adjoined to the dural sinus [2, 3, [5] [6] [7] [11] [12] [13] [14] [15] [16] [17] . Therefore, unless the dural sinus is sacrificed or reconstructed, it is difficult to literally completely remove the tumor in most cases.
The results of recent studies on the treatment strategies for intracranial HPCs suggest that both the extent of surgical resection and adjuvant RT are associated with significantly improved OS and RFS [2, [5] [6] [7] [8] [11] [12] [13] [14] 16] . However, as mentioned above, most previous studies do not define the meaning of "complete resection" or "GTR". Only 2 reports define the complete tumor resection as Simpson grade 1 [18, 19] . The "gross total" or "complete" resection rate reported in the liter- ature varied between 50 and 83% [2] [3] [4] 6, 8, 11, 12, 15, 17, 20, 21] . However, because of the location of tumor, these high rates of complete resection appear to be unreliable. The possibility stands that these might not be Simpson grade 1 removal. Similarly, our experience suggests that GTR was accomplished in 64.7%, while Simpson grade 1 removal was achieved in only 11.8% in which tumors were located at convexity.
As suggested by Bassiouni et al. [18] , the classification introduced by Simpson [9] in 1957 to describe the resection rate in meningiomas can also be usefully applied in intracranial HPCs, since, in most cases, these tumors are dura-based. We divided GTR into 3 Simpson grades, grades 1 to 3. The results of the statistical analysis of the correlation between the extent of resection and recurrence suggest statistical significance like other several studies (Fig. 6) [18, 19] . Conventional classification of dividing into GTR, PR and biopsy showed that each class of resection is significantly associated with RFS; Simpson grading system showed statistically significant correlations between each grade and RFS as well. To prevent local recurrence, it seems to be safer to remove the tumor as much as possible, even when the remaining tumor is adjoined to the adjacent structures, such as the dural sinus.
In many series, intracranial HPCs have been shown to re- Correlation analysis between the extent of resection and recurrence-free survival (log-rank test). GTR, grossly total resection; PR, partial resection. cur even after complete GTR. Therefore, several authors have recommended adjuvant RT for a better outcome [2, 5, 6, 8, 11, [13] [14] [15] [16] [17] 20, 21] . Similarly to other series, our experience shows that the patients who received adjuvant RT tend to have longer RFS (Fig. 7) . We performed adjuvant RT regardless of the extent of resection and pathologic grade in most of the patients. 16 out of 17 patients (94.1%) received adjuvant RT to the median dose of 57.57 Gy (range, 50 to 60 Gy) by median 33 fractions (range, 30-40 fractions); no significant radiation-related complications were observed. Although our result has serious limitation to compare with other series; a 1 versus 16 matchup among adjuvant RT effectiveness. Additional study should be done later on to certify effectiveness. The results of the statistical analysis of RFS depending on the pathologic diagnosis suggest that the median time values for local recurrence in the patients with WHO grade II HPC and WHO grade III HPC were 66.2 months and 38.1 months, respectively. However, possibly due to the small number of the investigated cases, this difference did not reach statistical significance.
In conclusion, surgical resection of intracranial HPC, in an attempt to reach Simpson grade 1 removal of the tumor, is necessary to reduce recurrence. But this attempt to reach Simpson grade 1 removal should be performed within the safe limit. Additionally, as recommended before, adjuvant RT should be done to prevent recurrence, even in the patients who have tumor completely resected and who have been diagnosed as WHO grade II HPC.
